REAL-WORLD EVIDENCE NEWSLETTER:
ISSUE 25

WHAT’S INSIDE:

  • New RWE publication
    Prognostic significance of patient-reported outcomes in cancer
  • New RWE publication
    First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis
  • New white paper
    Adding real-world evidence to a totality of evidence approach for evaluating marketed product effectiveness
  • Connect with Flatiron at these upcoming events
 

Research

Published in JCO Oncology Practice

Prognostic significance of patient-reported outcomes in cancer

Performance status (PS), while often used as a prognostic surrogate of cancer survival, may be prone to bias due to its reliance on a physician’s subjective interpretation of a patient’s status. The National Cancer Institute (NCI) Patient-Reported Outcomes Measurement Information System–Cancer (PROMIS-Ca) Bank, on the other hand, relies on patient-reported outcomes (PROs) to monitor patient status, eliminating the potential biases from physician interpretation.

In collaboration with Huntsman Cancer Institute, we looked at whether PROMIS-Ca can also be used as a prognostic indicator for overall survival and hospitalization-free survival (HFS).

Research

Published in Future Oncology

First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis

Standard first-line treatment of advanced urothelial cell carcinoma involves cisplatin-based chemotherapy, with carboplatin or immune checkpoint inhibitor therapy (ICI) reserved for cisplatin-ineligible individuals. However, due to the general tolerability of ICI and its lack of the traditional toxicities of chemotherapy, oncologists and cisplatin-eligible patients may opt to bypass cisplatin-based chemotherapy in favor of ICI in first-line settings.

In partnership with researchers from the University of Pennsylvania and Tisch Cancer Institute, we examined trends in the utilization of first-line systemic therapies in cisplatin-eligible patients.

IN CASE YOU MISSED IT

New white paper: Adding Real-World Evidence to a Totality of Evidence Approach for Evaluating Marketed Product Effectiveness

The Duke-Margolis Center for Health Policy released a new white paper last month. In it, they describe a framework for how RWE may contribute to regulatory decisions about the effectiveness of drugs as part of the “totality of evidence” submitted to FDA.

Connect with Flatiron

Upcoming events

March 4–6

Washington, DC

Speakers:

James Hamrick, MD, Senior Medical Director

Sharang Phadke, Product Manager, Machine Learning Platforms

Nirav R. Shah, MD, MPH, Head Revenue Cycle Operations

April 23–24

Orlando, FL

233 Spring Street, Floor 5

New York, NY 10013

© 2020 Flatiron Health, Inc. All Rights Reserved.